Esperion Therapeutics (ESPR) EBITDA (2012 - 2026)

Esperion Therapeutics' EBITDA history runs 15 years deep, the most recent figure standing at -$6.6 million for Q1 2026.

• Quarterly EBITDA rose 70.22% year-over-year to -$6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.8 million (up 289.65% YoY) and the FY2025 annual result came in at $60.3 million, up 10.79% from the prior year.
• EBITDA was -$6.6 million for Q1 2026 at Esperion Therapeutics, down from $85.2 million in the prior quarter.
• Across five years, EBITDA topped out at $85.2 million in Q4 2025 and bottomed at -$52.4 million in Q2 2022.
• A 5-year average of -$13.4 million and a median of -$22.1 million in 2025 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 2028.35% in 2025, while the deepest fall reached 130.57% in 2025.
• Esperion Therapeutics' EBITDA stood at -$42.5 million in 2022, then advanced by 0.34% to -$42.4 million in 2023, then soared by 89.57% to -$4.4 million in 2024, then surged by 2028.35% to $85.2 million in 2025, then plunged by 107.72% to -$6.6 million in 2026.
• Business Quant data shows ESPR's EBITDA at -$6.6 million in Q1 2026, $85.2 million in Q4 2025, and -$10.0 million in Q3 2025.